Benjamin Wingfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benjamin Wingfield has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Samuel Alec Lambert
Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4 shared publications - Anthony John Bjourson
Personalised Medicine Centre, School of Medicine, C-TRIC, Altnagelvin Hospital, Ulster University, Derry/Londonderry BT47 6SB, UK
3 shared publications - Aoife McMahon
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK
3 shared publications - Michael Inouye
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
3 shared publications - Andrew English
Teeside University, UK
2 shared publications Andrew P. Morris
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK
2 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by Center for Open Science in BioHackrXiv
A Blueprint for Open Science: How Transatlantic Teams Built and Deployed Knowledge Graphs to Enable Biological (AI) Models
Knowledge graphs (KGs) and large language models (LLMs) are increasingly applied in biomedical research; however, LLMs' tendency to hallucinate and lack of evidence traceability poses significant challenges for rigorous scientific applications. To address these limitations, the NVIDIA - AWS Open Data Knowledge Graph Hackathon, which brought together transatlantic teams, catalyzed the development of novel frameworks that built or integrated KGs with graph-based retrieval-augmented generation (GraphRAG) to enhance evidence-grounded generative AI. The hackathon took place on October 1-3, 2025, at two locations - the AWS Skills Center in Arlington, VA, USA and the European Bioinformatics Institute (EBI) Training Center in Cambridge, UK. Across seven prototype projects, participating teams developed systems that construct, validate, and deploy biomedical KGs using open data and cloud-native infrastructure. These included GeNETwork, which integrates pediatric oncology datasets to identify therapeutic targets; ECoGraph, a multi-omics graph framework for characterizing colorectal cancer drivers; ClassiGraph, a graph neural network classifier for cancer subtypes; EasyGiraffe, a validator for multisite polygenicity extraction; MIDAS (Model Integration and Data Assembly System), a pipeline for harmonizing heterogeneous biomedical datasets; KG Model Garbage Collection, a framework for detecting and pruning erroneous AI-generated edges; and BioGraphRAG, which combines precision medicine and literature-derived KGs for evidence-based question answering. Together, these prototypes demonstrate practical strategies for constructing and deploying biomedical KGs and highlight the potential of GraphRAG to produce interpretable, verifiable AI-driven insights. By emphasizing open data, reproducible pipelines, and evidence-grounded reasoning, this work advances methodologies for trustworthy generative AI in biomedical discovery.
- 26 November 2025
- Published by Center for Open Science in BioHackrXiv
Open AccessA Blueprint for Open Science: How Transatlantic Teams Built and Deployed Knowledge Graphs to Enable Biological (AI) Models
Knowledge graphs (KGs) and large language models (LLMs) are increasingly applied in biomedical research; however, LLMs' tendency to hallucinate and lack of evidence traceability poses significant challenges for rigorous scientific applications. To address these limitations, the NVIDIA - AWS Open Data Knowledge Graph Hackathon, which brought together transatlantic teams, catalyzed the development of novel frameworks that built or integrated KGs with graph-based retrieval-augmented generation (GraphRAG) to enhance evidence-grounded generative AI. The hackathon took place on October 1-3, 2025, at two locations - the AWS Skills Center in Arlington, VA, USA and the European Bioinformatics Institute (EBI) Training Center in Cambridge, UK. Across seven prototype projects, participating teams developed systems that construct, validate, and deploy biomedical KGs using open data and cloud-native infrastructure. These included GeNETwork, which integrates pediatric oncology datasets to identify therapeutic targets; ECoGraph, a multi-omics graph framework for characterizing colorectal cancer drivers; ClassiGraph, a graph neural network classifier for cancer subtypes; EasyGiraffe, a validator for multisite polygenicity extraction; MIDAS (Model Integration and Data Assembly System), a pipeline for harmonizing heterogeneous biomedical datasets; KG Model Garbage Collection, a framework for detecting and pruning erroneous AI-generated edges; and BioGraphRAG, which combines precision medicine and literature-derived KGs for evidence-based question answering. Together, these prototypes demonstrate practical strategies for constructing and deploying biomedical KGs and highlight the potential of GraphRAG to produce interpretable, verifiable AI-driven insights. By emphasizing open data, reproducible pipelines, and evidence-grounded reasoning, this work advances methodologies for trustworthy generative AI in biomedical discovery.
- Open Access
- 3 March 2025
- Published by EMBL-EBI
Polygenic Scores and the PGS Catalog
Polygenic scores (PGS) can be used to predict an individual's genetic predisposition to a heritable trait or disease. In this tutorial you will learn about PGS and the PGS Catalog, an open database of existing scores that can be reused and applied in research and clinical settings.
- 3 March 2025
- Published by EMBL-EBI
Open AccessPolygenic Scores and the PGS Catalog
Polygenic scores (PGS) can be used to predict an individual's genetic predisposition to a heritable trait or disease. In this tutorial you will learn about PGS and the PGS Catalog, an open database of existing scores that can be reused and applied in research and clinical settings.
- Open Access
- 4 December 2024
- Published by EMBL-EBI
Calculating polygenic scores with the Polygenic Score Catalog Calculator
Polygenic scores (PGS) are a measurement which represents genetic predisposition for a heritable trait or phenotype by aggregating the effects of hundreds-to-millions of genetic variants into a single number. The PGS Catalog is the world’s largest FAIR (finable, accessible, interoperable, and reusable) repository of PGS along with the relevant metadata required to evaluate and reuse them. PGS have emerged as a commonly used genomic tool that have multiple research applications and potential clinical applications. This webinar will demonstrate how to use scoring files from the PGS Catalog (or custom files) to calculate PGS in your own samples using the PGS Catalog Calculator (pgsc_calc). The pgsc_calc software reproducibly automates PGS calculation in commonly used genotyping formats (plink, VCF) alongside capabilities for adjusting PGS in the context of genetic ancestry (necessary for proper interpretation of PGS across diverse populations). This webinar introduces the software and describes the ancestry adjustment process included in the Calculator, along with information about how to run the tool and interpret results.
- 4 December 2024
- Published by EMBL-EBI
Open AccessCalculating polygenic scores with the Polygenic Score Catalog Calculator
Polygenic scores (PGS) are a measurement which represents genetic predisposition for a heritable trait or phenotype by aggregating the effects of hundreds-to-millions of genetic variants into a single number. The PGS Catalog is the world’s largest FAIR (finable, accessible, interoperable, and reusable) repository of PGS along with the relevant metadata required to evaluate and reuse them. PGS have emerged as a commonly used genomic tool that have multiple research applications and potential clinical applications. This webinar will demonstrate how to use scoring files from the PGS Catalog (or custom files) to calculate PGS in your own samples using the PGS Catalog Calculator (pgsc_calc). The pgsc_calc software reproducibly automates PGS calculation in commonly used genotyping formats (plink, VCF) alongside capabilities for adjusting PGS in the context of genetic ancestry (necessary for proper interpretation of PGS across diverse populations). This webinar introduces the software and describes the ancestry adjustment process included in the Calculator, along with information about how to run the tool and interpret results.
- Top Cited Papers
- 26 September 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 1989-1994
Enhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization
Polygenic scores (PGSs) have transformed human genetic research and have numerous potential clinical applications. Here we present a series of recent enhancements to the PGS Catalog and highlight the PGS Catalog Calculator, an open-source, scalable and portable pipeline for reproducibly calculating PGSs that democratizes equitable PGS applications.
- 26 September 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 1989-1994
Top Cited PapersEnhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization
Polygenic scores (PGSs) have transformed human genetic research and have numerous potential clinical applications. Here we present a series of recent enhancements to the PGS Catalog and highlight the PGS Catalog Calculator, an open-source, scalable and portable pipeline for reproducibly calculating PGSs that democratizes equitable PGS applications.
- Open Access
The Polygenic Score Catalog: new functionality and tools to enable FAIR research
Polygenic scores (PGS) have transformed human genetic research and have multiple potential clinical applications, including risk stratification for disease prevention and prediction of treatment response. Here, we present a series of recent enhancements to the PGS Catalog ( www.PGSCatalog.org ), the largest findable, accessible, interoperable, and reusable (FAIR) repository of PGS. These include expansions in data content and ancestral diversity as well as the addition of new features. We further present the PGS Catalog Calculator ( pgsc_calc , https://github.com/PGScatalog/pgsc_calc ), an open-source, scalable and portable pipeline to reproducibly calculate PGS that securely democratizes equitable PGS applications by implementing genetic ancestry estimation and score normalization using reference data. With the PGS Catalog & calculator users can now quantify an individual’s genetic predisposition for hundreds of common diseases and clinically relevant traits. Taken together, these updates and tools facilitate the next generation of PGS, thus lowering barriers to the clinical studies necessary to identify where PGS may be integrated into clinical practice.
Open AccessThe Polygenic Score Catalog: new functionality and tools to enable FAIR research
Polygenic scores (PGS) have transformed human genetic research and have multiple potential clinical applications, including risk stratification for disease prevention and prediction of treatment response. Here, we present a series of recent enhancements to the PGS Catalog ( www.PGSCatalog.org ), the largest findable, accessible, interoperable, and reusable (FAIR) repository of PGS. These include expansions in data content and ancestral diversity as well as the addition of new features. We further present the PGS Catalog Calculator ( pgsc_calc , https://github.com/PGScatalog/pgsc_calc ), an open-source, scalable and portable pipeline to reproducibly calculate PGS that securely democratizes equitable PGS applications by implementing genetic ancestry estimation and score normalization using reference data. With the PGS Catalog & calculator users can now quantify an individual’s genetic predisposition for hundreds of common diseases and clinically relevant traits. Taken together, these updates and tools facilitate the next generation of PGS, thus lowering barriers to the clinical studies necessary to identify where PGS may be integrated into clinical practice.
- Open Access
- 14 February 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e50733
Genomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study
Background: Health organizations and countries around the world have found it difficult to control the spread of COVID-19. To minimize the future impact on the UK National Health Service and improve patient care, there is a pressing need to identify individuals who are at a higher risk of being hospitalized because of severe COVID-19. Early targeted work was successful in identifying angiotensin-converting enzyme-2 receptors and type II transmembrane serine protease dependency as drivers of severe infection. Although a targeted approach highlights key pathways, a multiomics approach will provide a clearer and more comprehensive picture of severe COVID-19 etiology and progression. Objective: The COVID-19 Response Study aims to carry out an integrated multiomics analysis to identify biomarkers in blood and saliva that could contribute to host susceptibility to SARS-CoV-2 and the development of severe COVID-19. Methods: The COVID-19 Response Study aims to recruit 1000 people who recovered from SARS-CoV-2 infection in both community and hospital settings on the island of Ireland. This protocol describes the retrospective observational study component carried out in Northern Ireland (NI; Cohort A); the Republic of Ireland cohort will be described separately. For all NI participants (n=519), SARS-CoV-2 infection has been confirmed by reverse transcription-quantitative polymerase chain reaction. A prospective Cohort B of 40 patients is also being followed up at 1, 3, 6, and 12 months postinfection to assess longitudinal symptom frequency and immune response. Data will be sourced from whole blood, saliva samples, and clinical data from the electronic care records, the general health questionnaire, and a 12-item general health questionnaire mental health survey. Saliva and blood samples were processed to extract DNA and RNA before whole-genome sequencing, RNA sequencing, DNA methylation analysis, microbiome analysis, 16S ribosomal RNA gene sequencing, and proteomic analysis were performed on the plasma. Multiomics data will be combined with clinical data to produce sensitive and specific prognostic models for severity risk. Results: An initial demographic and clinical profile of the NI Cohort A has been completed. A total of 249 hospitalized patients and 270 nonhospitalized patients were recruited, of whom 184 (64.3%) were female, and the mean age was 45.4 (SD 13) years. High levels of comorbidity were evident in the hospitalized cohort, with cardiovascular disease and metabolic and respiratory disorders being the most significant (P<.001), grouped according to the International Classification of Diseases 10 codes. Conclusions: This study will provide a comprehensive opportunity to study the mechanisms of COVID-19 severity in recontactable participants. International Registered Report Identifier (IRRID): DERR1-10.2196/50733
- 14 February 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e50733
Open AccessGenomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study
Background: Health organizations and countries around the world have found it difficult to control the spread of COVID-19. To minimize the future impact on the UK National Health Service and improve patient care, there is a pressing need to identify individuals who are at a higher risk of being hospitalized because of severe COVID-19. Early targeted work was successful in identifying angiotensin-converting enzyme-2 receptors and type II transmembrane serine protease dependency as drivers of severe infection. Although a targeted approach highlights key pathways, a multiomics approach will provide a clearer and more comprehensive picture of severe COVID-19 etiology and progression. Objective: The COVID-19 Response Study aims to carry out an integrated multiomics analysis to identify biomarkers in blood and saliva that could contribute to host susceptibility to SARS-CoV-2 and the development of severe COVID-19. Methods: The COVID-19 Response Study aims to recruit 1000 people who recovered from SARS-CoV-2 infection in both community and hospital settings on the island of Ireland. This protocol describes the retrospective observational study component carried out in Northern Ireland (NI; Cohort A); the Republic of Ireland cohort will be described separately. For all NI participants (n=519), SARS-CoV-2 infection has been confirmed by reverse transcription-quantitative polymerase chain reaction. A prospective Cohort B of 40 patients is also being followed up at 1, 3, 6, and 12 months postinfection to assess longitudinal symptom frequency and immune response. Data will be sourced from whole blood, saliva samples, and clinical data from the electronic care records, the general health questionnaire, and a 12-item general health questionnaire mental health survey. Saliva and blood samples were processed to extract DNA and RNA before whole-genome sequencing, RNA sequencing, DNA methylation analysis, microbiome analysis, 16S ribosomal RNA gene sequencing, and proteomic analysis were performed on the plasma. Multiomics data will be combined with clinical data to produce sensitive and specific prognostic models for severity risk. Results: An initial demographic and clinical profile of the NI Cohort A has been completed. A total of 249 hospitalized patients and 270 nonhospitalized patients were recruited, of whom 184 (64.3%) were female, and the mean age was 45.4 (SD 13) years. High levels of comorbidity were evident in the hospitalized cohort, with cardiovascular disease and metabolic and respiratory disorders being the most significant (P<.001), grouped according to the International Classification of Diseases 10 codes. Conclusions: This study will provide a comprehensive opportunity to study the mechanisms of COVID-19 severity in recontactable participants. International Registered Report Identifier (IRRID): DERR1-10.2196/50733
- Open Access
Evaluation of polygenic scoring methods in five biobanks reveals greater variability between biobanks than between methods and highlights benefits of ensemble learning
Methods to estimate polygenic scores (PGS) from genome-wide association studies are increasingly utilized. However, independent method evaluation is lacking, and method comparisons are often limited. Here, we evaluate polygenic scores derived using seven methods in five biobank studies (totaling about 1.2 million participants) across 16 diseases and quantitative traits, building on a reference-standardized framework. We conducted meta-analyses to quantify the effects of method choice, hyperparameter tuning, method ensembling and target biobank on PGS performance. We found that no single method consistently outperformed all others. PGS effect sizes were more variable between biobanks than between methods within biobanks when methods were well-tuned. Differences between methods were largest for the two investigated autoimmune diseases, seropositive rheumatoid arthritis and type 1 diabetes. For most methods, cross-validation was more reliable for tuning hyperparameters than automatic tuning (without the use of target data). For a given target phenotype, elastic net models combining PGS across methods (ensemble PGS) tuned in the UK Biobank provided consistent, high, and cross-biobank transferable performance, increasing PGS effect sizes (β-coefficients) by a median of 5.0% relative to LDpred2 and MegaPRS (the two best performing single methods when tuned with cross-validation). Our interactively browsable online-results ( https://methodscomparison.intervenegeneticscores.org/ ) and open-source workflow prspipe ( https://github.com/intervene-EU-H2020/prspipe ) provide a rich resource and reference for the analysis of polygenic scoring methods across biobanks.
Open AccessEvaluation of polygenic scoring methods in five biobanks reveals greater variability between biobanks than between methods and highlights benefits of ensemble learning
Methods to estimate polygenic scores (PGS) from genome-wide association studies are increasingly utilized. However, independent method evaluation is lacking, and method comparisons are often limited. Here, we evaluate polygenic scores derived using seven methods in five biobank studies (totaling about 1.2 million participants) across 16 diseases and quantitative traits, building on a reference-standardized framework. We conducted meta-analyses to quantify the effects of method choice, hyperparameter tuning, method ensembling and target biobank on PGS performance. We found that no single method consistently outperformed all others. PGS effect sizes were more variable between biobanks than between methods within biobanks when methods were well-tuned. Differences between methods were largest for the two investigated autoimmune diseases, seropositive rheumatoid arthritis and type 1 diabetes. For most methods, cross-validation was more reliable for tuning hyperparameters than automatic tuning (without the use of target data). For a given target phenotype, elastic net models combining PGS across methods (ensemble PGS) tuned in the UK Biobank provided consistent, high, and cross-biobank transferable performance, increasing PGS effect sizes (β-coefficients) by a median of 5.0% relative to LDpred2 and MegaPRS (the two best performing single methods when tuned with cross-validation). Our interactively browsable online-results ( https://methodscomparison.intervenegeneticscores.org/ ) and open-source workflow prspipe ( https://github.com/intervene-EU-H2020/prspipe ) provide a rich resource and reference for the analysis of polygenic scoring methods across biobanks.
- Open Access
- 11 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Genomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study (Preprint)
BACKGROUND Health organizations and countries around the world have found it difficult to control the spread of COVID-19. To minimize the future impact on the UK National Health Service and improve patient care, there is a pressing need to identify individuals who are at a higher risk of being hospitalized because of severe COVID-19. Early targeted work was successful in identifying angiotensin-converting enzyme-2 receptors and type II transmembrane serine protease dependency as drivers of severe infection. Although a targeted approach highlights key pathways, a multiomics approach will provide a clearer and more comprehensive picture of severe COVID-19 etiology and progression. OBJECTIVE The COVID-19 Response Study aims to carry out an integrated multiomics analysis to identify biomarkers in blood and saliva that could contribute to host susceptibility to SARS-CoV-2 and the development of severe COVID-19. METHODS The COVID-19 Response Study aims to recruit 1000 people who recovered from SARS-CoV-2 infection in both community and hospital settings on the island of Ireland. This protocol describes the retrospective observational study component carried out in Northern Ireland (NI; Cohort A); the Republic of Ireland cohort will be described separately. For all NI participants (n=519), SARS-CoV-2 infection has been confirmed by reverse transcription-quantitative polymerase chain reaction. A prospective Cohort B of 40 patients is also being followed up at 1, 3, 6, and 12 months postinfection to assess longitudinal symptom frequency and immune response. Data will be sourced from whole blood, saliva samples, and clinical data from the electronic care records, the general health questionnaire, and a 12-item general health questionnaire mental health survey. Saliva and blood samples were processed to extract DNA and RNA before whole-genome sequencing, RNA sequencing, DNA methylation analysis, microbiome analysis, 16S ribosomal RNA gene sequencing, and proteomic analysis were performed on the plasma. Multiomics data will be combined with clinical data to produce sensitive and specific prognostic models for severity risk. RESULTS An initial demographic and clinical profile of the NI Cohort A has been completed. A total of 249 hospitalized patients and 270 nonhospitalized patients were recruited, of whom 184 (64.3%) were female, and the mean age was 45.4 (SD 13) years. High levels of comorbidity were evident in the hospitalized cohort, with cardiovascular disease and metabolic and respiratory disorders being the most significant (P<.001), grouped according to the International Classification of Diseases 10 codes. CONCLUSIONS This study will provide a comprehensive opportunity to study the mechanisms of COVID-19 severity in recontactable participants. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/50733
- 11 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessGenomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study (Preprint)
BACKGROUND Health organizations and countries around the world have found it difficult to control the spread of COVID-19. To minimize the future impact on the UK National Health Service and improve patient care, there is a pressing need to identify individuals who are at a higher risk of being hospitalized because of severe COVID-19. Early targeted work was successful in identifying angiotensin-converting enzyme-2 receptors and type II transmembrane serine protease dependency as drivers of severe infection. Although a targeted approach highlights key pathways, a multiomics approach will provide a clearer and more comprehensive picture of severe COVID-19 etiology and progression. OBJECTIVE The COVID-19 Response Study aims to carry out an integrated multiomics analysis to identify biomarkers in blood and saliva that could contribute to host susceptibility to SARS-CoV-2 and the development of severe COVID-19. METHODS The COVID-19 Response Study aims to recruit 1000 people who recovered from SARS-CoV-2 infection in both community and hospital settings on the island of Ireland. This protocol describes the retrospective observational study component carried out in Northern Ireland (NI; Cohort A); the Republic of Ireland cohort will be described separately. For all NI participants (n=519), SARS-CoV-2 infection has been confirmed by reverse transcription-quantitative polymerase chain reaction. A prospective Cohort B of 40 patients is also being followed up at 1, 3, 6, and 12 months postinfection to assess longitudinal symptom frequency and immune response. Data will be sourced from whole blood, saliva samples, and clinical data from the electronic care records, the general health questionnaire, and a 12-item general health questionnaire mental health survey. Saliva and blood samples were processed to extract DNA and RNA before whole-genome sequencing, RNA sequencing, DNA methylation analysis, microbiome analysis, 16S ribosomal RNA gene sequencing, and proteomic analysis were performed on the plasma. Multiomics data will be combined with clinical data to produce sensitive and specific prognostic models for severity risk. RESULTS An initial demographic and clinical profile of the NI Cohort A has been completed. A total of 249 hospitalized patients and 270 nonhospitalized patients were recruited, of whom 184 (64.3%) were female, and the mean age was 45.4 (SD 13) years. High levels of comorbidity were evident in the hospitalized cohort, with cardiovascular disease and metabolic and respiratory disorders being the most significant (P<.001), grouped according to the International Classification of Diseases 10 codes. CONCLUSIONS This study will provide a comprehensive opportunity to study the mechanisms of COVID-19 severity in recontactable participants. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/50733
- Open Access
- 29 November 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 567
snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data
Quality control of genomic data is an essential but complicated multi-step procedure, often requiring separate installation and expert familiarity with a combination of different bioinformatics tools. Software incompatibilities, and inconsistencies across computing environments, are recurrent challenges, leading to poor reproducibility. Existing semi-automated or automated solutions lack comprehensive quality checks, flexible workflow architecture, and user control. To address these challenges, we have developed snpQT: a scalable, stand-alone software pipeline using nextflow and BioContainers, for comprehensive, reproducible and interactive quality control of human genomic data. snpQT offers some 36 discrete quality filters or correction steps in a complete standardised pipeline, producing graphical reports to demonstrate the state of data before and after each quality control procedure. This includes human genome build conversion, population stratification against data from the 1,000 Genomes Project, automated population outlier removal, and built-in imputation with its own pre- and post- quality controls. Common input formats are used, and a synthetic dataset and comprehensive online tutorial are provided for testing, educational purposes, and demonstration. The snpQT pipeline is designed to run with minimal user input and coding experience; quality control steps are implemented with numerous user-modifiable thresholds, and workflows can be flexibly combined in custom combinations. snpQT is open source and freely available at https://github.com/nebfield/snpQT. A comprehensive online tutorial and installation guide is provided through to GWAS (https://snpqt.readthedocs.io/en/latest/), introducing snpQT using a synthetic demonstration dataset and a real-world Amyotrophic Lateral Sclerosis SNP-array dataset.
- 29 November 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 567
Open AccesssnpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data
Quality control of genomic data is an essential but complicated multi-step procedure, often requiring separate installation and expert familiarity with a combination of different bioinformatics tools. Software incompatibilities, and inconsistencies across computing environments, are recurrent challenges, leading to poor reproducibility. Existing semi-automated or automated solutions lack comprehensive quality checks, flexible workflow architecture, and user control. To address these challenges, we have developed snpQT: a scalable, stand-alone software pipeline using nextflow and BioContainers, for comprehensive, reproducible and interactive quality control of human genomic data. snpQT offers some 36 discrete quality filters or correction steps in a complete standardised pipeline, producing graphical reports to demonstrate the state of data before and after each quality control procedure. This includes human genome build conversion, population stratification against data from the 1,000 Genomes Project, automated population outlier removal, and built-in imputation with its own pre- and post- quality controls. Common input formats are used, and a synthetic dataset and comprehensive online tutorial are provided for testing, educational purposes, and demonstration. The snpQT pipeline is designed to run with minimal user input and coding experience; quality control steps are implemented with numerous user-modifiable thresholds, and workflows can be flexibly combined in custom combinations. snpQT is open source and freely available at https://github.com/nebfield/snpQT. A comprehensive online tutorial and installation guide is provided through to GWAS (https://snpqt.readthedocs.io/en/latest/), introducing snpQT using a synthetic demonstration dataset and a real-world Amyotrophic Lateral Sclerosis SNP-array dataset.
- Open Access
- 14 July 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 567
snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data
Quality control of genomic data is an essential but complicated multi-step procedure, often requiring separate installation and expert familiarity with a combination of different bioinformatics tools. Dependency hell and reproducibility are recurrent challenges. Existing semi-automated or automated solutions lack comprehensive quality checks, flexible workflow architecture, and user control. To address these challenges, we have developed snpQT: a scalable, stand-alone software pipeline using nextflow and BioContainers, for comprehensive, reproducible and interactive quality control of human genomic data. snpQT offers some 36 discrete quality filters or correction steps in a complete standardised pipeline, producing graphical reports to demonstrate the state of data before and after each quality control procedure. This includes human genome build conversion, population stratification against data from the 1,000 Genomes Project, automated population outlier removal, and built-in imputation with its own pre- and post- quality controls. Common input formats are used, and a synthetic dataset and comprehensive online tutorial are provided for testing, educational purposes, and demonstration. The snpQT pipeline is designed to run with minimal user input and coding experience; quality control steps are implemented with default thresholds which can be modified by the user, and workflows can be flexibly combined in custom combinations. snpQT is open source and freely available at https://github.com/nebfield/snpQT. A comprehensive online tutorial and installation guide is provided through to GWAS (https://snpqt.readthedocs.io/en/latest/), introducing snpQT using a synthetic demonstration dataset and a real-world Amyotrophic Lateral Sclerosis SNP-array dataset.
- 14 July 2021
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 567
Open AccesssnpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data
Quality control of genomic data is an essential but complicated multi-step procedure, often requiring separate installation and expert familiarity with a combination of different bioinformatics tools. Dependency hell and reproducibility are recurrent challenges. Existing semi-automated or automated solutions lack comprehensive quality checks, flexible workflow architecture, and user control. To address these challenges, we have developed snpQT: a scalable, stand-alone software pipeline using nextflow and BioContainers, for comprehensive, reproducible and interactive quality control of human genomic data. snpQT offers some 36 discrete quality filters or correction steps in a complete standardised pipeline, producing graphical reports to demonstrate the state of data before and after each quality control procedure. This includes human genome build conversion, population stratification against data from the 1,000 Genomes Project, automated population outlier removal, and built-in imputation with its own pre- and post- quality controls. Common input formats are used, and a synthetic dataset and comprehensive online tutorial are provided for testing, educational purposes, and demonstration. The snpQT pipeline is designed to run with minimal user input and coding experience; quality control steps are implemented with default thresholds which can be modified by the user, and workflows can be flexibly combined in custom combinations. snpQT is open source and freely available at https://github.com/nebfield/snpQT. A comprehensive online tutorial and installation guide is provided through to GWAS (https://snpqt.readthedocs.io/en/latest/), introducing snpQT using a synthetic demonstration dataset and a real-world Amyotrophic Lateral Sclerosis SNP-array dataset.